Market News
Global Intramuscular Vaccine Adjuvants Market Recent Developments:
New product launches
- MF59: MF59 is an adjuvant used in influenza vaccines, which was first approved by the FDA in 1997. In recent years, new formulations of MF59 have been developed, such as MF59C.1, which has been used in the Novartis Fluad vaccine for older adults.
- AS03: AS03 is an adjuvant used in the H1N1 pandemic vaccine, which was approved by the FDA in 2009. AS03 has also been used in the GlaxoSmithKline Shingrix vaccine for shingles, which was approved in 2017.
- CpG 1018: CpG 1018 is a synthetic adjuvant used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. It has been shown to enhance the immune response and increase vaccine efficacy.
- Advax: Advax is an adjuvant developed by Vaxine Pty Ltd, which has been shown to enhance the immune response in preclinical studies. Advax is being developed for use in vaccines for infectious diseases and cancer.
- Matrix-M: Matrix-M is an adjuvant developed by Novavax, which has been shown to enhance the immune response and increase vaccine efficacy. Matrix-M has been used in the Novavax COVID-19 vaccine, which is currently being evaluated by regulatory agencies for approval.
Acquisition and partnerships
- In 2021, Croda International acquired Brenntag Biosector, a global leader in adjuvant technologies, to expand their portfolio of adjuvant products and improve their market position.
- In 2020, Vaxine Pty Ltd entered into a partnership with Medytox Inc. to develop a COVID-19 vaccine using Vaxine's adjuvant technology.
Global Intramuscular Vaccine Adjuvants Market Recent Developments:
U.S.: 
U.K. : 
India : 
